The Effect of ASTARTE17; Lactobacillus Crispatus, Lactobacillus Rhamnosus, Lactobacillus Jenesii and Lactobacillus Gasseri on the Reduction of Risk Factors for Recurrent Urinary Tract Infection in Women

What this Trial Is About

Researchers are studying the effect of a dietary supplement called ASTARTE17, which contains four probiotic strains (Lactobacillus crispatus, L. rhamnosus, L. jensenii, and L. gasseri), on the microbiome in the intestine and vagina. The study focuses on women aged 18 to 40 years who have recurrent urinary tract infections (rUTI). The goal is to see if ASTARTE17 can reduce risk factors for rUTI, measured by the number of symptomatic UTIs over six months. Participants will take one capsule daily for six months. One group will receive the ASTARTE17 probiotic capsules, while the other group will receive placebo capsules identical in appearance but without the probiotic strains. The study is randomized and double-blind, meaning neither participants nor researchers know who receives which capsules. The study will map bacterial composition in urine, feces, and vaginal samples to examine relationships between microbiota and urinary tract infections. During the study, participants will be monitored for urinary tract infection occurrences and changes in the vaginal and gut microbiome at six and twelve months. Researchers will collect samples and evaluate symptoms and the number of infections. The study also includes safety monitoring and follows participants for up to two years, with the primary outcome being the reduction of UTI cases after six months of treatment.

The Effect of ASTARTE™ on Recurrent Urinary Tract Infection